Compare BTU & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | WGS |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2001 | 2020 |
| Metric | BTU | WGS |
|---|---|---|
| Price | $15.46 | $45.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $24.17 | ★ $82.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,861,500,000.00 | $427,539,000.00 |
| Revenue This Year | $11.01 | $11.40 |
| Revenue Next Year | $1.79 | $19.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $15.69 | $32.21 |
| 52 Week High | $41.14 | $170.87 |
| Indicator | BTU | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 25.33 | 33.81 |
| Support Level | N/A | $32.21 |
| Resistance Level | $24.53 | $72.65 |
| Average True Range (ATR) | 1.00 | 5.39 |
| MACD | -0.00 | -0.98 |
| Stochastic Oscillator | 3.63 | 4.82 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.